Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Stock Info Message Board

Genocea Biosciences Inc. (GNCA) News Nov 20, 2014,

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 250666
Posted On: 11/20/2014 8:52:26 PM
Posted By: Savant
Genocea Biosciences Inc. (GNCA) News Nov 20, 2014, 5:14 p.m.
MarketWatch News on GNCA
U.S. stocks fall; data stoke fears of slowdown 4:31 p.m. Feb. 5, 2014 - Anora Mahmudova
Stocks dip, end off day's lows; Twitter falls after hours: stock market live blog recap 4:27 p.m. Feb. 5, 2014 - blogs.marketwatch.com
3D Systems down on weak outlook, CVS quits cigarettes 4:17 p.m. Feb. 5, 2014 - Sue Chang
Biotech startups find welcome mat withdrawn during IPOs 2:44 p.m. Feb. 5, 2014 - Russ Britt

Other News on GNCA
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2014 Results - Earnings Call Transcript 12:49 p.m. Nov. 6, 2014 - Seeking Alpha
10-Q: GENOCEA BIOSCIENCES, INC. 11:50 a.m. Nov. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog 1:57 p.m. Oct. 9, 2014 - Zacks.com
10-Q: GENOCEA BIOSCIENCES, INC. 1:06 p.m. Aug. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Genocea Biosciences (GNCA) Chip Clark on Q2 2014 Results - Earnings Call Transcript 10:12 a.m. Aug. 6, 2014 - Seeking Alpha
Genocea starts Phase 2 for herpes drug candidate 8:05 a.m. July 21, 2014 - Seeking Alpha
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape 7:44 a.m. July 17, 2014 - Zacks.com
Genocea Biosciences (GNCA) Jumps: Stock Rises 8.7% - Tale of the Tape 8:39 a.m. June 23, 2014 - Zacks.com
10-Q: GENOCEA BIOSCIENCES, INC. 1:44 p.m. May 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-K: GENOCEA BIOSCIENCES, INC. 2:33 p.m. March 21, 2014 - Edgar Online - (EDG = 10Q, 10K)
Press Releases on GNCA
Genocea Named in Top Places to Work List by The Boston Globe 11:52 a.m. Nov. 13, 2014 - BusinessWire - BZX
Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference 8:04 a.m. Nov. 12, 2014 - BusinessWire - BZX
Genocea Reports Third Quarter 2014 Financial Results 8:01 a.m. Nov. 6, 2014 - BusinessWire - BZX
Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes 12:01 p.m. Nov. 5, 2014 - BusinessWire - BZX
Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014 8:04 a.m. Oct. 30, 2014 - BusinessWire - BZX
Genocea Presents Complete Phase 1/2a Data for HSV-2 Immunotherapy at IDWeek 8:03 a.m. Oct. 8, 2014 - BusinessWire - BZX
Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery 7:01 a.m. Sept. 23, 2014 - BusinessWire - BZX
Genocea to Present at the 21st Annual NewsMakers in the Biotech Industry Conference 8:01 a.m. Sept. 19, 2014 - BusinessWire - BZX
Virology Publishes Genocea HSV-2 Antigen Discovery Paper 8:03 a.m. Sept. 16, 2014 - BusinessWire - BZX
Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate 1:00 p.m. Sept. 11, 2014 - BusinessWire - BZX
Genocea Appoints Kenneth Bate to its Board of Directors 11:30 a.m. Sept. 11, 2014 - BusinessWire - BZX
Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC 3:22 p.m. Sept. 6, 2014 - BusinessWire - BZX
Genocea Reports Second Quarter 2014 Financial Results 10:38 p.m. Aug. 6, 2014 - BusinessWire - BZX
Genocea to Announce Second Quarter 2014 Financial Resultson August 6, 2014 7:02 a.m. July 30, 2014 - BusinessWire - BZX
Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects 7:03 a.m. July 22, 2014 - BusinessWire - BZX
Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy 7:02 a.m. July 21, 2014 - BusinessWire - BZX
Genocea Biosciences, Inc. Elects Not to Pursue Public Offering 10:30 a.m. July 16, 2014 - BusinessWire - BZX
Genocea Biosciences, Inc. Commences Public Offering of Common Stock 6:30 a.m. July 14, 2014 - BusinessWire - BZX
Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003 7:02 a.m. July 1, 2014 - BusinessWire - BZX
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer 6:30 a.m. June 24, 2014 - BusinessWire - BZX



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us